» Articles » PMID: 29241991

Pancreatic Cyst Fluid Glucose: Rapid, Inexpensive, and Accurate Diagnosis of Mucinous Pancreatic Cysts

Overview
Journal Surgery
Specialty General Surgery
Date 2017 Dec 16
PMID 29241991
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The most widely accepted biochemical test for preoperative differentiation of mucinous from benign, nonmucinous pancreatic cysts is cyst fluid carcinoembryonic antigen. However, the diagnostic accuracy of carcinoembryonic antigen ranges from 70% to 86%. Based on previous work, we hypothesize that pancreatic cyst fluid glucose may be an attractive alternative to carcinoembryonic antigen.

Methods: Pancreatic cyst fluid was collected during endoscopic or operative intervention. Diagnoses were pathologically confirmed. Glucose and carcinoembryonic antigen were measured using a patient glucometer and automated analyzer/enzyme-linked immunosorbent assay. Sensitivity, specificity, accuracy, and receiver operator characteristic analyses were performed.

Results: Cyst fluid samples from 153 patients were evaluated (mucinous: 25 mucinous cystic neoplasms, 77 intraductal papillary mucinous neoplasms, 4 ductal adenocarcinomas; nonmucinous: 21 serous cystic neoplasms, 9 cystic neuroendocrine tumors, 14 pseudocysts, 3 solid pseudopapillary neoplasms). Median cyst fluid glucose was lower in mucinous versus nonmucinous cysts (19 vs 96 mg/dL; P < .0001). With a threshold of ≤ 50 mg/dL, cyst fluid glucose was 92% sensitive, 87% specific, and 90% accurate in diagnosing mucinous pancreatic cysts. In comparison, cyst fluid carcinoembryonic antigen with a threshold of >192 ng/mL was 58% sensitive, 96% specific, and 69% accurate. Area under the curve for glucose and CEA were similar at 0.91 and 0.92.

Conclusion: Cyst fluid glucose has significant advantages over carcinoembryonic antigen and should be considered for use as a routine diagnostic test for pancreatic mucinous cysts.

Citing Articles

Intracystic Glucose Measurement for On-Site Differentiation Between Mucinous and Non-Mucinous Pancreatic Cystic Lesions.

Bruni A, Eusebi L, Lisotti A, Ricci C, Maida M, Fusaroli P Cancers (Basel). 2025; 16(24.

PMID: 39766096 PMC: 11674768. DOI: 10.3390/cancers16244198.


Thermal Liquid Biopsy: A Promising Tool for the Differential Diagnosis of Pancreatic Cystic Lesions and Malignancy Detection.

Millastre J, Hermoso-Duran S, Solorzano M, Fraunhoffer N, Garcia-Rayado G, Vega S Cancers (Basel). 2024; 16(23).

PMID: 39682210 PMC: 11640424. DOI: 10.3390/cancers16234024.


Diagnostics and Management of Pancreatic Cystic Lesions-New Techniques and Guidelines.

Rogowska J, Semeradt J, Durko L, Malecka-Wojciesko E J Clin Med. 2024; 13(16).

PMID: 39200786 PMC: 11355509. DOI: 10.3390/jcm13164644.


Addressing the unmet clinical need for low-volume assays in early diagnosis of pancreatic cancer.

Sheik D, Byers K, Thomas M, Rajesh U, Ifuku K, Kirkwood K Front Gastroenterol (Lausanne). 2024; 2.

PMID: 38846269 PMC: 11156210. DOI: 10.3389/fgstr.2023.1258998.


Neutrophil Gelatinase-Associated Lipocalin for the Differentiation of Mucinous Pancreatic Cystic Lesions.

Olar M, Iacobescu M, Bolboaca S, Pojoga C, Mosteanu O, Seicean R Int J Mol Sci. 2024; 25(6).

PMID: 38542201 PMC: 10970073. DOI: 10.3390/ijms25063224.